308.54

0.35% -1.095

Insulet Corporation (PODD)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché PODD Giù? Forum Previsione

Precedente Chiudi:

$309.63

Aprire:

$312.04

Volume 24 ore:

399.49K

Relative Volume:

0.50

Capitalizzazione di mercato:

$21.70B

Reddito:

$2.20B

Utile/perdita netta:

$402.20M

Rapporto P/E:

55.49

EPS:

5.56

Flusso di cassa netto:

$280.80M

1 W Prestazione:

+11.26%

1M Prestazione:

+6.64%

6M Prestazione:

+9.36%

1 anno Prestazione:

+58.56%

Intervallo 1D:

$306.91

$314.35

Intervallo di 1 settimana:

$286.68

$322.80

Portata 52W:

$180.31

$329.33

Insulet Corporation Stock (PODD) Company Profile

Nome

Insulet Corporation

Settore

Healthcare (1164)

Industria

Medical Devices (150)

Telefono

978-600-7000

Indirizzo

100 NAGOG PARK, ACTON, MA

Dipendente

3,900

Cinguettio

@insulet_uk

Prossima data di guadagno

2024-11-07

Ultimi documenti SEC

PODD's Discussions on Twitter

Confronta PODD con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
PODD Insulet Corporation	308.41	21.46B	2.20B	402.20M	280.80M	5.56
ABT Abbott Laboratories	129.33	228.63B	43.11B	13.98B	6.78B	7.98
BSX Boston Scientific Corp	102.78	152.25B	18.49B	2.51B	3.23B	1.68
SYK Stryker Corp	377.78	144.00B	23.82B	2.92B	4.02B	7.55
MDT Medtronic Plc	92.94	118.82B	33.54B	4.66B	5.19B	3.62
EW Edwards Lifesciences Corp	77.87	45.89B	5.69B	4.14B	577.90M	6.96

Insulet Corporation Stock (PODD) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-06-16	Iniziato	Truist	Buy
2025-05-30	Iniziato	Goldman	Buy
2025-05-13	Aggiornamento	Wolfe Research	Peer Perform → Outperform
2025-04-29	Downgrade	Wolfe Research	Outperform → Peer Perform
2025-03-06	Iniziato	RBC Capital Mkts	Outperform
2024-11-06	Iniziato	Bernstein	Outperform
2024-05-30	Iniziato	Redburn Atlantic	Buy
2024-05-07	Aggiornamento	Wolfe Research	Peer Perform → Outperform
2023-12-21	Aggiornamento	Robert W. Baird	Neutral → Outperform
2023-12-04	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2023-10-02	Aggiornamento	Jefferies	Hold → Buy
2023-08-21	Aggiornamento	Citigroup	Neutral → Buy
2023-08-21	Downgrade	Robert W. Baird	Outperform → Neutral
2023-05-30	Ripresa	Morgan Stanley	Equal-Weight
2023-01-26	Iniziato	Wolfe Research	Peer Perform
2022-11-04	Aggiornamento	Piper Sandler	Neutral → Overweight
2022-10-18	Iniziato	Barclays	Equal Weight
2022-10-12	Iniziato	Jefferies	Hold
2022-07-11	Downgrade	Citigroup	Buy → Neutral
2022-03-02	Ripresa	BofA Securities	Buy
2022-02-03	Aggiornamento	BTIG Research	Neutral → Buy
2022-02-02	Aggiornamento	UBS	Neutral → Buy
2022-01-31	Aggiornamento	Oppenheimer	Perform → Outperform
2021-07-21	Ripresa	Cowen	Outperform
2021-05-25	Iniziato	Barclays	Overweight
2021-04-01	Aggiornamento	SVB Leerink	Mkt Perform → Outperform
2021-03-19	Aggiornamento	Canaccord Genuity	Hold → Buy
2021-01-29	Downgrade	Piper Sandler	Overweight → Neutral
2020-12-16	Downgrade	Citigroup	Buy → Neutral
2020-07-28	Iniziato	Wells Fargo	Overweight
2020-04-24	Downgrade	SVB Leerink	Outperform → Mkt Perform
2020-04-03	Iniziato	BofA/Merrill	Neutral
2020-03-31	Downgrade	Berenberg	Buy → Hold
2020-03-05	Iniziato	Citigroup	Buy
2019-12-10	Iniziato	CFRA	Sell
2019-10-23	Iniziato	Stifel	Hold
2019-10-18	Downgrade	Canaccord Genuity	Buy → Hold
2019-10-14	Downgrade	BTIG Research	Buy → Neutral
2019-10-04	Downgrade	UBS	Buy → Neutral
2019-10-03	Downgrade	Guggenheim	Buy → Neutral
2019-08-06	Aggiornamento	JP Morgan	Neutral → Overweight
2019-06-10	Downgrade	Northland Capital	Outperform → Market Perform
2019-05-06	Aggiornamento	BTIG Research	Neutral → Buy
2018-04-20	Iniziato	Berenberg	Buy
2018-02-22	Reiterato	Barclays	Overweight
2018-01-08	Aggiornamento	Raymond James	Mkt Perform → Outperform
2017-11-03	Aggiornamento	Canaccord Genuity	Hold → Buy
2017-09-15	Iniziato	Barclays	Overweight

Mostra tutto

Insulet Corporation Borsa (PODD) Ultime notizie

02:00 AM

Quant Strategy Flags Insulet Corporation for EntryJuly 2025 Patterns & Weekly Chart Analysis and Guides - 선데이타임즈

02:00 AM

Aug 12, 2025

PODD Q2 Deep Dive: Omnipod 5 Adoption and International Expansion Drive Results - ca.finance.yahoo.com

Aug 12, 2025

Insulet Q2 Earnings & Revenues Beat Estimates, Stock Up, Margins Rise - TradingView

Aug 12, 2025

Why Insulet (PODD) Is Up 7.8% After Raising Full-Year Revenue Guidance on Omnipod Momentum - simplywall.st

Aug 11, 2025

Aug 10, 2025

Price Consolidation Hints at Upcoming Move in Insulet CorporationFast Exit and Entry Strategy Guide Offered - beatles.ru

Aug 10, 2025

Insulin pump makers Tandem and Insulet post contrasting Q2 results - MSN

Aug 10, 2025

Aug 09, 2025

Insulet's Insider Activity and Executive Compensation Transparency: A Governance and Investor Sentiment Analysis - AInvest

Aug 09, 2025

Aug 08, 2025

Research Alert: CFRA Maintains Hold Opinion On Shares Of Insulet Corporation - 富途牛牛

Aug 08, 2025

RBC Capital Raises PT for Insulet to $350, Maintains Outperform Rating - AInvest

Aug 08, 2025

Insulet Corporation shares rise 2.61% intraday after multiple brokerages raised price targets. - AInvest

Aug 08, 2025

Insulet (PODD) Is Up 5.3% After Raising Full-Year Revenue Guidance on Strong Q2 Sales – Has The Bull Case Changed? - simplywall.st

Aug 08, 2025

Baird Adjusts Price Target on Insulet to $360 From $350, Maintains Outperform Rating - MarketScreener

Aug 08, 2025

Insulet stock price target raised to $350 from $330 at RBC Capital - Investing.com Canada

Aug 08, 2025

Bernstein raises Insulet stock price target to $400 on type 2 diabetes growth - Investing.com Nigeria

Aug 08, 2025

RBC Raises Price Target on Insulet to $350 From $330, Keeps Outperform Rating - MarketScreener

Aug 08, 2025

Insulet price target raised to $350 from $330 at RBC Capital - TipRanks

Aug 08, 2025